fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Melatonin and its derivatives enhance long-term object recognition memory

Written by | 23 Aug 2023

Multiple studies have demonstrated the memory-enhancing effects of melatonin and its derivatives in animal models. It is also known that the formation of both short- and long-term memories… read more.

How do testosterone’s effects on the brain change from adolescence into adulthood?

Written by | 14 Jul 2023

Higher testosterone levels during adolescence are associated with increased involvement of the brain’s anterior prefrontal cortex (aPFC) in emotion control, but the opposite effect occurs during adulthood. In… read more.

Palliative care: Creating a new model to address suffering for neurological illnesses

Written by | 30 Jun 2023

Neurologic illnesses, including Alzheimer’s, brain cancer, amyotrophic lateral sclerosis (ALS) and stroke, are among the most dreaded illnesses in medicine and leading causes of disability and death worldwide…. read more.

Positive CHMP opinion for atogepant for the preventive treatment of adults with migraine – AbbVie

Written by | 29 Jun 2023

AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the… read more.

Health Canada approves Xcopri to treat partial offset seizures – Paladin Labs

Written by | 26 Jun 2023

SK Biopharmaceuticals said that Health Canada granted a Notice of Compliance for Xcopri (ingredient: cenobamate), its epilepsy drug, approving its application for marketing authorization in Canada. Paladin Labs,… read more.

New drug delays progression of glioma, a deadly brain cancer

Written by | 7 Jun 2023

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma… read more.

Ketamine nasal spray may prove safe and effective treatment for refractory migraine

Written by | 3 Jun 2023

Ketamine taken in the form of a nasal spray may prove a safe and effective treatment for refractory chronic migraine, suggests a single centre study, published in the… read more.

Drug significantly reduces chorea symptoms in patients with Huntington’s disease

Written by | 23 May 2023

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher… read more.

Atogepant shows efficacy for prevention of migraine

Written by | 14 May 2023

Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.

Almost half of people with concussion still show symptoms of brain injury six months later

Written by | 27 Apr 2023

Even mild concussion can cause long-lasting effects to the brain, according to researchers at the University of Cambridge. Using data from a Europe-wide study, the team has shown… read more.

Diabetes drug shows promise for “blinding headache” condition

Written by | 23 Apr 2023

Exenatide, an injectable treatment for type 2 diabetes, has shown efficacy for the treatment of ‘blinding’ headaches known as idiopathic intercranial hypertension (IIH). Researchers from a phase 2… read more.

Is bone health linked to brain health?

Written by | 29 Mar 2023

People who have low bone density may have an increased risk of developing dementia compared to people who have higher bone density, according to a study published in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.